Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00225056
(Terminated due to lack of accrual)
In this phase II study, we plan to evaluate the efficacy, safety and tolerability of weekly docetaxel and capecitabine on a 21-day cycle followed by maintenance single agent capecitabine for the treatment of metastatic breast cancer, Based on the efficacy and toxicity of the combination regimen dosages previously reviewed; weekly docetaxel 30mg/m2 on days 1 and 8 plus capecitabine 1600mg/m2 (800mg/m2 orally twice daily)on day 1 through 14 of each cycle will be utilized.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
19 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
must have metastatic breast cancer
must have cytologically or pathologically confirmed invasive ductal or lobular carcinoma
must have measurable or evaluable disease
ECOG of 0-1
patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer
must have adequate organ function
must be at least 19 years of age
peripheral neuropathy less than or equal to grade 1
must have voluntarily signed informed consent
patients with brain metastases are eligible provided that other measurable disease exists and brain lesions are controlled
patients with other malignancies, except non melanoma of the skin, who have had any evidence of cancer within the last 5 years
patients with psychiatric illness or other concurrent severe co-morbid medical condition that would preclude study completion
known uncontrolled existing coagulopathy
patients with a history of severe hypersensitivity reaction to docetaxel, medications formulated with polysorbate 80 or 5-fluorouracil
use of other investigational agents in the last 28 days
pregnant or lactating women
patients who are known HIV positive
patients with life expectancy of less than 3 months
sexually active patients unwilling to practice reliable contraception during the study